Hancock Jaffe Laboratories, Inc.

39 articles about Hancock Jaffe Laboratories, Inc.

• Hancock Jaffe to Participate in the Duologue Series Virtual Webinar Hosted by Ladenburg Thalmann

  9/24/2021

  Live webinar followed by Q&A on Monday, September 27th at 1:00 PM ET with Robert Berman Chief Executive Officer of Hancock Jaffe Laboratories

• Hancock Jaffe Announces Corporate Rebranding to Reflect Prioritization of its Development Pipeline on Venous Disease Programs

  9/21/2021

  Hancock Jaffe Laboratories, Inc., a medical device company focused on improving the standard of care in the treatment of venous disease, announced a corporate update which includes a planned corporate rebranding and strategic prioritization of the Company's development pipeline.

• Hancock Jaffe to Host Corporate Update Conference Call and Webcast on September 21, 2021

  9/15/2021

  Hancock Jaffe Laboratories, Inc. today announced that Hancock Jaffe management will host a corporate update conference call with a live video webcast on Tuesday, September 21, 2021 at 4:30 p.m. ET.

• Hancock Jaffe Laboratories Announces $20 Million Registered Direct Offering Priced At-the-Market Under NASDAQ Rules

  9/7/2021

  Hancock Jaffe Laboratories, Inc. , today announced that it has entered into a definitive agreement with a fund managed by Perceptive Advisors to purchase $20 million of its common stock and pre-funded warrants in a registered direct offering priced at-the-market under Nasdaq rules.

• Hancock Jaffe Presents New Positive Two-Year VenoValve Data at the Society for Vascular Surgery Annual Meeting

  8/19/2021

  Hancock Jaffe Laboratories, Inc. announced that promising two-year post-VenoValve® implantation data is being presented today at the Society for Vascular Surgery® (SVS) Annual Meeting in San Diego, CA by Dr. Jorge Ulloa, who was the Principal Investigator for the Company's first-in-human VenoValve trial.

• FDA Grants Breakthrough Device Designation Status for Hancock Jaffe's VenoValve

  8/3/2021

  Hancock Jaffe Laboratories today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Device Designation status to the VenoValve®

• Hancock Jaffe to Present at the Ladenburg Thalmann 2021 Healthcare Conference

  7/8/2021

  Hancock Jaffe Laboratories, Inc., a developer of medical devices that restore cardiac and vascular health, announced that Robert Berman, CEO of Hancock Jaffe will present at the Ladenburg Thalmann 2021 Healthcare Conference on Tuesday, July 13, 2021 at 1:00 PM ET.

• Hancock Jaffe Principal Investigator Dr. Jorge Hernando Ulloa Presents VenoValve One Year First-In-Human Data at Charing Cross International Symposium

  4/23/2021

  Hancock Jaffe Laboratories, Inc. (NASDAQ:HJLI), a developer of medical devices that restore cardiac and vascular health, today announced that Dr. Jorge Hernando Ulloa, the Principal Investigator for HJLI first-in-human VenoValve study in Bogota, Colombia, presented one year data this past week at the Charing Cross International Symposium.

• First U.S. Patent Issues on Hancock Jaffe VenoValve

  4/7/2021

  Hancock Jaffe Laboratories, Inc. (NASDAQ:HJLI), a developer of medical devices that restore cardiac and vascular health, today announced that the United States Patent and Trademark Office (USPTO) has issued the first patent covering the companys VenoValve.

• Hancock Jaffe Receives IDE Approval To Begin VenoValve U.S. Pivotal Trial

  4/5/2021

  Hancock Jaffe Laboratories, Inc. (NASDAQ:HJLI), a developer of medical devices that restore cardiac and vascular health, today announced that the U.S. Food and Drug Administration (FDA) has approved the companys Investigational Device Exemption (IDE) application to begin the U.S. pivotal trial for the VenoValve.

• Hancock Jaffe Submits IDE Application to FDA for VenoValve U.S. Pivotal Trial

  3/8/2021

  Hancock Jaffe Laboratories, Inc., a developer of medical devices that restore cardiac and vascular health, announced that it has submitted an Investigational Device Exemption application to the U.S. Food and Drug Administration seeking approval to begin a U.S. pivotal trial for the VenoValve®.

• Hancock Jaffe Completes $41 Million Public Offering

  2/11/2021

  Hancock Jaffe Laboratories, Inc. (NASDAQ:HJLI), a developer of medical devices that restore cardiac and vascular health, today announced that it has successfully completed a public offering of its securities generating approximately $41.4 million of gross proceeds, prior to deducting underwriting discounts and commissions, and expenses.

• Hancock Jaffe Laboratories Announces Pricing of Upsized $36 Million Offering

  2/9/2021

  Hancock Jaffe Laboratories, Inc. (NASDAQ:HJLI), a developer of medical devices that restore cardiac and vascular health, today announced the pricing of its upsized underwritten public offering of units for gross proceeds of approximately $36 million, prior to deducting underwriting discounts and commissions and offering expenses payable by the company.

• Hancock Jaffe Concludes Successful VenoValve Pre-IDE Meeting with FDA

  1/12/2021

  Hancock Jaffe Laboratories, Inc. (NASDAQ:HJLI), a developer of medical devices that restore cardiac and vascular health, today announced that it has successfully concluded its VenoValve Pre-IDE meeting with the U.S. Food and Drug Administration .

• Hancock Jaffe Announces Executive Promotions

  12/30/2020

  Hancock Jaffe Laboratories, Inc., a developer of medical devices that restore cardiac and vascular health, announced that Dr. Hamed Alavi has been promoted to Vice President of Research and Development and Quality and that Craig Glynn has accepted the position of Chief Financial Officer.

• Hancock Jaffe Deemed Compliant With All NASDAQ Continued Listing Requirements

  12/21/2020

  Hancock Jaffe Laboratories, Inc. (NASDAQ:HJLI), a developer of medical devices that restore cardiac and vascular health, today announced that the Company has received formal notification from the NASDAQ Hearings Panel (the "Panel") that the Company has evidenced full compliance with the minimum bid price requirement and all other applicable criteria for continued listin

• Hancock Jaffe Reports Two CoreoGraft Patients Have Reached 30 Day Milestone

  12/16/2020

  Hancock Jaffe Laboratories, Inc. (NASDAQ:HJLI), a developer of medical devices that restore cardiac and vascular health, today announced that two patients who have undergone heart bypass surgeries utilizing HJLIs CoreoGraft have reached the 30-day milestone and are reported to have good cardiac function.

• Hancock Jaffe Announces Significant Improvements in all Study Endpoints For Final VenoValve First-in-Human Data

  12/15/2020

  Hancock Jaffe Laboratories, Inc. (NASDAQ:HJLI)(NASDAQ:HJLIW), a developer of medical devices that restore cardiac and vascular health, announced today that the final aggregated data for the VenoValve first-in-human trial shows significant improvements in all study endpoints. For the eleven patients in the first-in-human study, reflux (the backwards flow of blood)

• Hancock Jaffe Announces One Year Follow-up Data on Eleventh VenoValve Patient

  12/14/2020

  Hancock Jaffe Laboratories, Inc. (NASDAQ:HJLI)(NASDAQ:HJLIW), a developer of medical devices that restore cardiac and vascular health, announced today that the eleventh and final VenoValve patient in HJLIs first-in-human, clinical study has successfully reached the one-year milestone. Patient 11&39s chronic venous insufficiency

• Hancock Jaffe to Provide VenoValve and CoreoGraft Updates at Ladenburg Thalmann R&D Showcase Webinar on December 16, 2020

  12/10/2020

  Hancock Jaffe Laboratories, Inc. (NASDAQ:HJLI), a developer of medical devices that restore cardiac and vascular health, today announced that on Wednesday, December 16, 2020, at 1:00 Eastern time,